Zenbexus (iberdomide) got FDA accelerated approval for multiple myeloma as the first in the new class of oral targeted protein degraders that BMS is developing to supplant the older IMiD class.
Zenbexus (iberdomide) got FDA accelerated approval for multiple myeloma as the first in the new class of oral targeted protein degraders that BMS is developing to supplant the older IMiD class.